JP2008540538A - （ｓ）−３−（３−（３−メトキシ−４−（オキサゾール−５−イル）フェニル）ウレイド）ベンジルカルバミン酸テトラヒドロフラン−３−イルの多形形態 - Google Patents

（ｓ）−３−（３−（３−メトキシ−４−（オキサゾール−５−イル）フェニル）ウレイド）ベンジルカルバミン酸テトラヒドロフラン−３−イルの多形形態 Download PDF

Info

Publication number
JP2008540538A
JP2008540538A JP2008511227A JP2008511227A JP2008540538A JP 2008540538 A JP2008540538 A JP 2008540538A JP 2008511227 A JP2008511227 A JP 2008511227A JP 2008511227 A JP2008511227 A JP 2008511227A JP 2008540538 A JP2008540538 A JP 2008540538A
Authority
JP
Japan
Prior art keywords
degrees
polymorph
virus
ureido
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008511227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008540538A5 (enExample
Inventor
デイビッド ティー． ジョナイティス，
スティーブン ディー． パーレン，
トッド エー． バイス，
マイケル ハレイ，
フィリップ エル． ナイス，
ジョン アール． スヌーニアン，
アレックス エーベルリーン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2008540538A publication Critical patent/JP2008540538A/ja
Publication of JP2008540538A5 publication Critical patent/JP2008540538A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008511227A 2005-05-09 2006-05-08 （ｓ）−３−（３−（３−メトキシ−４−（オキサゾール−５−イル）フェニル）ウレイド）ベンジルカルバミン酸テトラヒドロフラン−３−イルの多形形態 Pending JP2008540538A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67902105P 2005-05-09 2005-05-09
PCT/US2006/017693 WO2006122012A2 (en) 2005-05-09 2006-05-08 Polymorphic forms of (s)- tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) benzylcarbamate

Publications (2)

Publication Number Publication Date
JP2008540538A true JP2008540538A (ja) 2008-11-20
JP2008540538A5 JP2008540538A5 (enExample) 2009-06-25

Family

ID=37397198

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008511227A Pending JP2008540538A (ja) 2005-05-09 2006-05-08 （ｓ）−３−（３−（３−メトキシ−４−（オキサゾール−５−イル）フェニル）ウレイド）ベンジルカルバミン酸テトラヒドロフラン−３−イルの多形形態

Country Status (7)

Country Link
US (2) US7605270B2 (enExample)
EP (1) EP1891062A2 (enExample)
JP (1) JP2008540538A (enExample)
CN (1) CN101175752A (enExample)
AU (1) AU2006244204A1 (enExample)
CA (1) CA2606507A1 (enExample)
WO (1) WO2006122012A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540538A (ja) * 2005-05-09 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド （ｓ）−３−（３−（３−メトキシ−４−（オキサゾール−５−イル）フェニル）ウレイド）ベンジルカルバミン酸テトラヒドロフラン−３−イルの多形形態
WO2008070795A2 (en) * 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
US20110237605A1 (en) * 2010-03-26 2011-09-29 Eric Phillips Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative
WO2017223178A1 (en) * 2016-06-21 2017-12-28 Trek Therapeutics, Pbc Treating viral infections with impdh inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001509132A (ja) * 1996-04-23 2001-07-10 バーテックス ファーマシューティカルズ インコーポレイテッド Ｉｍｐｄｈ酵素のインヒビターとしての尿素誘導体
JP2005501890A (ja) * 2001-08-28 2005-01-20 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｈｃｖ感染処置用の最適組成物およびその方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
WO1997040028A1 (en) * 1996-04-23 1997-10-30 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
JP2008540538A (ja) * 2005-05-09 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド （ｓ）−３−（３−（３−メトキシ−４−（オキサゾール−５−イル）フェニル）ウレイド）ベンジルカルバミン酸テトラヒドロフラン−３−イルの多形形態

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001509132A (ja) * 1996-04-23 2001-07-10 バーテックス ファーマシューティカルズ インコーポレイテッド Ｉｍｐｄｈ酵素のインヒビターとしての尿素誘導体
JP2005501890A (ja) * 2001-08-28 2005-01-20 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｈｃｖ感染処置用の最適組成物およびその方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"医薬品の残留溶媒ガイドラインについて", 医薬審第３０７号, JPN6010003282, 1998, ISSN: 0002229775 *
"新医薬品の規格及び試験方法の設定について", 医薬審発第５６８号, JPN6010021254, 2001, ISSN: 0002229772 *
岡野定舗, 新・薬剤学総論, vol. 第３版, JPN6012005131, 10 April 1987 (1987-04-10), pages 111 - 256, ISSN: 0002229773 *
橋田充, 経口投与製剤の設計と評価, JPN6012005133, 10 February 1995 (1995-02-10), pages 79 - 171, ISSN: 0002229774 *

Also Published As

Publication number Publication date
US8153668B2 (en) 2012-04-10
EP1891062A2 (en) 2008-02-27
CN101175752A (zh) 2008-05-07
WO2006122012A2 (en) 2006-11-16
US20070281980A1 (en) 2007-12-06
WO2006122012A3 (en) 2007-03-08
CA2606507A1 (en) 2006-11-16
AU2006244204A1 (en) 2006-11-16
US20090324545A1 (en) 2009-12-31
US7605270B2 (en) 2009-10-20

Similar Documents

Publication Publication Date Title
JP4184610B2 (ja) Ｉｍｐｄｈ酵素のインヒビター
JP5566907B2 (ja) Ｎ−（ｔｅｒｔ−ブトキシカルボニル）−３−メチル−ｌ−バリル−（４ｒ）−４−（（７−クロロ−４−メトキシ−１−イソキノリニル）オキシ）−ｎ−（（１ｒ，２ｓ）−１−（（シクロプロピルスルホニル）カルバモイル）−２−ビニルシクロプロピル）−ｌ−プロリンアミドの結晶フォーム
JP2010535785A (ja) （（１ｓ）−１−（（（２ｓ）−２−（５−（４’−（２−（（２ｓ）−１−（（２ｓ）−２−（（メトキシカルボニル）アミノ）−３−メチルブタノイル）−２−ピロリジニル）−１ｈ−イミダゾール−５−イル）−４−ビフェニリル）−１ｈ−イミダゾール−２−イル）−１−ピロリジニル）カルボニル）−２−メチルプロピル）カルバミン酸メチル二塩酸塩の結晶形
NO312963B1 (no) Ureaderivater som inhibitorer av IMPDH-enzym
US8153668B2 (en) Polymorphic forms of (S)-1-tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate
US7829723B2 (en) Polymorphic forms of (S)-1-cyanobutan-2-yl (S)-1-(3-3-(3-methoxy-4-(oxazol-5-yl)phenyl)uriedo)phenyl)ethylcarbamate
HK1120257A (en) Polymorphic forms of (s)-tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl) ureido) benzylcarbamate
US7659309B2 (en) Polymorphic forms of (1-{3-[3-(4-cyano-3-methoxy-phenyl) ureido]-phenyl}-ethyl)-carbamic acid-2-cyano-1-ethyl-ethyl ester
HK1118288A (en) Polymorphic forms of (s)-1-cyanobutan-2-yl (s)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) phenyl) ethylcarbamate
Al-Masoudi et al. In vitro anti-HIV and HCV activity of new thioureido and thiazole analogues of cholesterol conjugated α-amino acid residues and in silico molecular modeling study.
HK1101039A (en) Polymorphic forms of (1-{3-[3-(4-cyano-3-methoxy-phenyl)ureido]-phenyl}-ethyl)-carbamic acid-2- cyano-1-ethyl-ethyl ester

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120521

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121023